PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Norepinephrine

Drugs in development · updated 30 October 2026

Norepinephrine: clinical trials and development status

NLM verified identityApproved in the US (FDA)

As of 30 October 2026 Norepinephrine is in 12 active clinical trials (recruiting or ongoing, phases I–III) for 16 diseases. The most advanced phase is III.

12Active trials
IIIMost advanced phase
16Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Norepinephrine and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Critical illnessIII1NCT06464510
Ischemic strokeIII1NCT06059144
SepsisIII1NCT05179499
Septic shockIII1NCT06464510
StrokeIII1NCT06059144
VasoplegiaIII1NCT05568160
Multiple TraumaI–II1NCT06977659
Pulmonary hypertensionII1NCT07614438
UrolithiasisI–II1NCT07786844
Wounds and InjuriesI–II1NCT06977659
Arterial hypertensionI2NCT02966665
Chronic obstructive pulmonary diseaseI1NCT02966665
Heart failureI1NCT02966665
Insulin resistanceI1NCT01426529
Primary pulmonary hypertensionI1NCT02966665
ObesityEarly I1NCT05219799

Everything on Norepinephrine

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch